Interestingly, as an inhibitor of JAK, ruxolitinib significantly reduced cytokine-mediated lung adenocarcinoma proliferation by inhibiting the JAK/STAT signal pathway [48]. The gene discussed is SOAT1; the disease is lung adenocarcinoma.